Harvard Bioscience IncNASDAQ:HBIO
- LAST PRICE3.3700
- TODAY'S CHANGE (%)-0.0700 (-2.0349%)
- Bid / Lots3.3000/ 10
- Ask / Lots3.6000/ 1
- Open / Previous Close3.4600 / 3.4400
- Day Range
- 52 Week Range
- Volume57,415
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | HBIO |
|---|---|---|
| 09:32 ET | 9625 | 3.46 |
| 09:48 ET | 3470 | 3.4 |
| 09:57 ET | 297 | 3.4129 |
| 10:21 ET | 100 | 3.445 |
| 10:35 ET | 600 | 3.445 |
| 11:04 ET | 5668 | 3.43 |
| 11:08 ET | 100 | 3.43 |
| 11:09 ET | 100 | 3.43 |
| 11:11 ET | 200 | 3.4 |
| 11:18 ET | 100 | 3.4 |
| 11:27 ET | 150 | 3.4104 |
| 11:56 ET | 1000 | 3.4305 |
| 11:58 ET | 2503 | 3.38 |
| 12:02 ET | 100 | 3.405 |
| 12:25 ET | 100 | 3.4255 |
| 12:30 ET | 100 | 3.4138 |
| 12:38 ET | 140 | 3.415 |
| 12:39 ET | 175 | 3.415 |
| 12:56 ET | 100 | 3.415 |
| 12:59 ET | 300 | 3.4 |
| 01:17 ET | 1100 | 3.41 |
| 01:21 ET | 200 | 3.4 |
| 01:35 ET | 100 | 3.4 |
| 02:27 ET | 100 | 3.405 |
| 02:45 ET | 100 | 3.4 |
| 02:49 ET | 656 | 3.385 |
| 02:54 ET | 100 | 3.3942 |
| 02:58 ET | 500 | 3.37 |
| 03:07 ET | 561 | 3.37 |
| 03:18 ET | 674 | 3.36 |
| 03:20 ET | 1251 | 3.365 |
| 03:30 ET | 100 | 3.365 |
| 03:32 ET | 232 | 3.365 |
| 03:43 ET | 100 | 3.36 |
| 03:45 ET | 100 | 3.36 |
| 03:48 ET | 300 | 3.36 |
| 03:50 ET | 200 | 3.38 |
| 03:52 ET | 200 | 3.385 |
| 03:54 ET | 100 | 3.38 |
| 03:56 ET | 200 | 3.37 |
| 03:57 ET | 700 | 3.35 |
| 03:59 ET | 400 | 3.37 |
May 16, 2024
Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference, from 4:05PM ET on Thursday May 16, 2024 by Dow Jones
4:05PM ET on Thursday May 16, 2024 by Dow Jones
May 7, 2024
*DJ Harvard Bioscience 1Q Loss/Shr 11c >HBIO, from 7:00AM ET on Tuesday May 07, 2024 by Dow Jones
7:00AM ET on Tuesday May 07, 2024 by Dow JonesHarvard Bioscience Announces First Quarter 2024 Financial Results, from 7:00AM ET on Tuesday May 07, 2024 by Dow Jones
7:00AM ET on Tuesday May 07, 2024 by Dow Jones
Apr 29, 2024
Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET, from 8:45AM ET on Monday Apr 29, 2024 by Dow Jones
8:45AM ET on Monday Apr 29, 2024 by Dow JonesPress Release: Harvard Bioscience Schedules First Quarter 2024 Earnings Conference Call for May 7, 2024 at 8:00 AM ET, from 8:45AM ET on Monday Apr 29, 2024 by Dow Jones
8:45AM ET on Monday Apr 29, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Harvard Bioscience Inc | 146.4M | -16.6x | --- |
Akoya Biosciences Inc | 140.6M | -1.9x | --- |
Fonar Corp | 102.3M | 10.3x | -15.67% |
Outset Medical Inc | 186.6M | -1.1x | --- |
ViewRay Inc | 180.0 | 0.0x | --- |
Xylo Technologies Ltd | 3.6M | -0.2x | --- |
Company Information
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.
Contact Information
- Headquarters
- 84 OCTOBER HILL RDHOLLISTON, MA, United States 01746
- Phone
- 508-893-8999
- Fax
- 508-429-5732
Executives
- Chairman of the Board, President, Chief Executive Officer
- James Green
- Chief Financial Officer, Treasurer
- Jennifer Cote
- Lead Independent Director
- Bertrand Loy
- Independent Director
- Katherine Eade
- Independent Director
- Alan Edrick
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $146.4M |
|---|---|
Revenue (TTM) | $106.8M |
Shares Outstanding | 43.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-0.20 |
Book Value | $1.68 |
P/E Ratio | -16.6x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2.00% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
